Abstract
Germline missense mutations in the tyrosine kinase domain of the hepatocyte growth factor / scatter factor (HGF / SF) receptor, c-Met, are thought to be responsible for hereditary papillary renal carcinoma (HPRC) type 1, a form of human kidney cancer. In addition to extensive linkage analysis of HPRC families localizing the HPRC type 1 gene within chromosome 7, the demonstration that individual c-Met mutations reconstituted in cultured cells display enhanced and dysregulated kinase activity, and confer cell transformation and tumorigenicity in mice, solidifies this conclusion. Our prior knowledge of HGF / SF biology and c-Met signaling enabled rapid progress in unraveling the molecular pathogenesis of HPRC type 1, and in laying the framework for the development of novel therapeutics for the treatment of this cancer. At the same time, the study of HPRC type 1 has refined our appreciation of the oncogenic potential of c-Met signaling, and challenges our current understanding of HGF / SF and c-Met function in health and disease.
Keywords: c-met, hgf/sf, hprc, missense mutations, renal carcinoma
Current Molecular Medicine
Title: Hereditary Papillary Renal Carcinoma Type I
Volume: 4 Issue: 8
Author(s): Pathirage G. Dharmawardana, Alessio Giubellino and Donald P. Bottaro
Affiliation:
Keywords: c-met, hgf/sf, hprc, missense mutations, renal carcinoma
Abstract: Germline missense mutations in the tyrosine kinase domain of the hepatocyte growth factor / scatter factor (HGF / SF) receptor, c-Met, are thought to be responsible for hereditary papillary renal carcinoma (HPRC) type 1, a form of human kidney cancer. In addition to extensive linkage analysis of HPRC families localizing the HPRC type 1 gene within chromosome 7, the demonstration that individual c-Met mutations reconstituted in cultured cells display enhanced and dysregulated kinase activity, and confer cell transformation and tumorigenicity in mice, solidifies this conclusion. Our prior knowledge of HGF / SF biology and c-Met signaling enabled rapid progress in unraveling the molecular pathogenesis of HPRC type 1, and in laying the framework for the development of novel therapeutics for the treatment of this cancer. At the same time, the study of HPRC type 1 has refined our appreciation of the oncogenic potential of c-Met signaling, and challenges our current understanding of HGF / SF and c-Met function in health and disease.
Export Options
About this article
Cite this article as:
Dharmawardana G. Pathirage, Giubellino Alessio and Bottaro P. Donald, Hereditary Papillary Renal Carcinoma Type I, Current Molecular Medicine 2004; 4 (8) . https://dx.doi.org/10.2174/1566524043359674
DOI https://dx.doi.org/10.2174/1566524043359674 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Circulating Biomarkers for Tumor Angiogenesis: Where Are We?
Current Medicinal Chemistry Role of Hsp70 in Cancer Growth and Survival
Protein & Peptide Letters The Ubiquitin-Proteasome Pathway and Resistance Mechanisms Developed Against the Proteasomal Inhibitors in Cancer Cells
Current Drug Targets Birt-hogg-Dubé Syndrome Incidentally Identified in a Potential Liver Donor
Current Medical Imaging Therapeutic Strategies to Target TGF-β in the Treatment of Bone Metastases
Current Pharmaceutical Biotechnology MicroRNAs in Renal Cell Carcinoma
MicroRNA Endometrial Cancer as a Familial Tumor: Pathology and Molecular Carcinogenesis (Review)
Current Genomics Membrane Targeted Chemotherapy with Hybrid Liposomes for Tumor Cells Leading to Apoptosis
Current Pharmaceutical Design Patent Analysis as a Tool for Research Planning: Study on Natural Based Therapeutics Against Cancer Stem Cells
Recent Patents on Anti-Cancer Drug Discovery Vertebral Lesions from AIDS-Related Kaposi's Sarcoma
Current HIV Research Angiogenesis as a Therapeutic Target in Arthritis: Lessons from Oncology
Current Pharmaceutical Design Targeting Receptor Tyrosine Kinases Using Monoclonal Antibodies: The Most Specific Tools for Targeted-Based Cancer Therapy
Current Drug Targets Patent Selections:
Recent Patents on Biomarkers Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
Current Pharmaceutical Design Tea (Camellia sinensis (L.)): A Putative Anticancer Agent in Bladder Carcinoma?
Anti-Cancer Agents in Medicinal Chemistry Neuroprotective Effects of Non-Classical Estrogen-Like Signaling Activators: from Mechanism to Potential Implications
CNS & Neurological Disorders - Drug Targets Highly Selective MEK Inhibitors
Current Enzyme Inhibition Advances in the Development of Multimodal Imaging Agents for Nuclear/Near-infrared Fluorescence Imaging
Current Medicinal Chemistry Small Molecules with EGFR-TK Inhibitor Activity
Current Drug Targets Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies